Press Releases

Press Releases
  Date Title and Summary View
Jan 17, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Jan. 17, 2007--ArQule, Inc. (Nasdaq: ARQL) today announced that Michael D. Loberg, Ph.D., has been named to its board of directors. Dr. Loberg brings 27 years of senior management and drug development experience to ArQule, including leadership positions at NitroMed, Inc. and Bristol Myers Squibb Company. ...
Jan 16, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Jan. 16, 2007--ArQule, Inc. (NASDAQ: ARQL) today provided an update on its clinical trials with three compounds: ARQ 197, a proprietary, orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase; ARQ 501, a first-generation Activated Checkpoint Therapy(SM) (ACT) candidate; and ARQ 171...
Page: FirstPrevious ...
= add release to Briefcase

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300